The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva

  title={The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite {\ss}-d-N4-hydroxycytidine in human plasma and saliva},
  author={Alieu Amara and Sujan Dilly Penchala and Laura J. Else and Colin Hale and Richard J Fitzgerald and Lauren Walker and Rebecca L. Lyons and Tom Fletcher and Saye H. Khoo},
  journal={Journal of pharmaceutical and biomedical analysis},
  pages={114356 - 114356}

Figures and Tables from this paper

Pharmacokinetics of β-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
Characterised the pharmacokinetics of NHC in saliva, nasal secretions and tears of patients enrolled in the phase I AGILE trial to understand its potential in preventing infection and transmission and have important implications for prophylactic coverage.


Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.
Practical, experimental approaches for studying, identifying, and eliminating the effect of matrix on the results of quantitative analyses by HPLC-MS/MS are described and it is demonstrated that, for the investigational drug under study, the matrix effect was clearly observed when ISP interface was utilized but it was absent when the HN interface was employed.
20α- and 20β-dihydrocortisone may interfere in LC-MS/MS determination of cortisol in saliva and urine
Cortisol determination by LC-MS/MS may suffer from erroneously elevated results unless 20α- and 20β-dihydrocortisone are chromatographically separated from cortisol.
Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2
Plasma exposures exceeded expected efficacious doses based on scaling from animal models; therefore, dose escalations were discontinued before a maximum tolerated dose was reached.
Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions.
A novel, robust LC-MS/MS assay for the combined measurement of SalF and SalE, which confirms the 11beta-HSD2 activity of the salivary glands resulting in high SalE concentrations and the enzyme saturation at high substrate concentrations.
Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
Low-level NHC resistance was difficult to achieve and was associated with multiple transition mutations across the genome in both MHV and MERS-CoV, indicating a high genetic barrier to N HC resistance.
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
Five days of DRV/c did not increase the proportion of negative conversion vs standard of care alone, although it was well tolerated, and the frequencies of adverse events in the 2 groups were comparable.
The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.
Preclinical characterization of a ribonucleoside analog EIDD-1931 (β-D-N4-hydroxycytidine, NHC), which has shown broad activity against alphaviruses in vitro and has a very high genetic barrier for development of resistance, is identified and pursued.
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
The ADME, safety, in vitro, and in vivo antiviral activity data that supports the clinical evaluation of this compound as a potential COVID-19 treatment are presented.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Molnupiravir was safe and well tolerated; a dose of 800mg twice-daily for 5 days was recommended for Phase II evaluation.
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  • Peter W Marion Jennifer L Louise Natalie Jonathan Adrian Horby Mafham Bell Linsell Staplin Emberson Palfree, P. Horby, +24 authors M. Landray
  • Medicine
    The Lancet
  • 2020
In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.